IBDEI0HE ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8452,1,4,0)
 ;;=4^709.2
 ;;^UTILITY(U,$J,358.3,8452,2)
 ;;=^108131
 ;;^UTILITY(U,$J,358.3,8453,0)
 ;;=710.0^^58^609^60
 ;;^UTILITY(U,$J,358.3,8453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8453,1,3,0)
 ;;=3^Lupus,Systemic Erythmatosis
 ;;^UTILITY(U,$J,358.3,8453,1,4,0)
 ;;=4^710.0
 ;;^UTILITY(U,$J,358.3,8453,2)
 ;;=^72159
 ;;^UTILITY(U,$J,358.3,8454,0)
 ;;=710.9^^58^609^10
 ;;^UTILITY(U,$J,358.3,8454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8454,1,3,0)
 ;;=3^Collagen Disease NOS
 ;;^UTILITY(U,$J,358.3,8454,1,4,0)
 ;;=4^710.9
 ;;^UTILITY(U,$J,358.3,8454,2)
 ;;=^123811
 ;;^UTILITY(U,$J,358.3,8455,0)
 ;;=714.0^^58^609^98
 ;;^UTILITY(U,$J,358.3,8455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8455,1,3,0)
 ;;=3^Rheumatoid Arthritis
 ;;^UTILITY(U,$J,358.3,8455,1,4,0)
 ;;=4^714.0
 ;;^UTILITY(U,$J,358.3,8455,2)
 ;;=^10473
 ;;^UTILITY(U,$J,358.3,8456,0)
 ;;=714.30^^58^609^99
 ;;^UTILITY(U,$J,358.3,8456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8456,1,3,0)
 ;;=3^Rheumatoid Arthritis,Juvenile
 ;;^UTILITY(U,$J,358.3,8456,1,4,0)
 ;;=4^714.30
 ;;^UTILITY(U,$J,358.3,8456,2)
 ;;=^24424
 ;;^UTILITY(U,$J,358.3,8457,0)
 ;;=744.89^^58^609^38
 ;;^UTILITY(U,$J,358.3,8457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8457,1,3,0)
 ;;=3^Face/Neck Anom NEC,Congenital
 ;;^UTILITY(U,$J,358.3,8457,1,4,0)
 ;;=4^744.89
 ;;^UTILITY(U,$J,358.3,8457,2)
 ;;=^272875
 ;;^UTILITY(U,$J,358.3,8458,0)
 ;;=759.6^^58^609^116
 ;;^UTILITY(U,$J,358.3,8458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8458,1,3,0)
 ;;=3^Von-Hippel Lindau Disease
 ;;^UTILITY(U,$J,358.3,8458,1,4,0)
 ;;=4^759.6
 ;;^UTILITY(U,$J,358.3,8458,2)
 ;;=^87431
 ;;^UTILITY(U,$J,358.3,8459,0)
 ;;=759.82^^58^609^62
 ;;^UTILITY(U,$J,358.3,8459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8459,1,3,0)
 ;;=3^Marfan Syndrome
 ;;^UTILITY(U,$J,358.3,8459,1,4,0)
 ;;=4^759.82
 ;;^UTILITY(U,$J,358.3,8459,2)
 ;;=^74034
 ;;^UTILITY(U,$J,358.3,8460,0)
 ;;=802.4^^58^609^36
 ;;^UTILITY(U,$J,358.3,8460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8460,1,3,0)
 ;;=3^FX Malar/Maxillary Bones,Closed
 ;;^UTILITY(U,$J,358.3,8460,1,4,0)
 ;;=4^802.4
 ;;^UTILITY(U,$J,358.3,8460,2)
 ;;=^25312
 ;;^UTILITY(U,$J,358.3,8461,0)
 ;;=870.1^^58^609^53
 ;;^UTILITY(U,$J,358.3,8461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8461,1,3,0)
 ;;=3^Laceration Full Thickness
 ;;^UTILITY(U,$J,358.3,8461,1,4,0)
 ;;=4^870.1
 ;;^UTILITY(U,$J,358.3,8461,2)
 ;;=^274880
 ;;^UTILITY(U,$J,358.3,8462,0)
 ;;=870.2^^58^609^34
 ;;^UTILITY(U,$J,358.3,8462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8462,1,3,0)
 ;;=3^Eyelid Laceration Involving Lacrimal
 ;;^UTILITY(U,$J,358.3,8462,1,4,0)
 ;;=4^870.2
 ;;^UTILITY(U,$J,358.3,8462,2)
 ;;=^274881
 ;;^UTILITY(U,$J,358.3,8463,0)
 ;;=870.3^^58^609^84
 ;;^UTILITY(U,$J,358.3,8463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8463,1,3,0)
 ;;=3^Orbital Wound,Penetrating
 ;;^UTILITY(U,$J,358.3,8463,1,4,0)
 ;;=4^870.3
 ;;^UTILITY(U,$J,358.3,8463,2)
 ;;=^274882
 ;;^UTILITY(U,$J,358.3,8464,0)
 ;;=870.9^^58^609^69
 ;;^UTILITY(U,$J,358.3,8464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8464,1,3,0)
 ;;=3^Ocular Adnexa Open Wound,Unspec
 ;;^UTILITY(U,$J,358.3,8464,1,4,0)
 ;;=4^870.9
 ;;^UTILITY(U,$J,358.3,8464,2)
 ;;=^274885
 ;;^UTILITY(U,$J,358.3,8465,0)
 ;;=871.0^^58^609^70
 ;;^UTILITY(U,$J,358.3,8465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8465,1,3,0)
 ;;=3^Ocular Laceration
 ;;^UTILITY(U,$J,358.3,8465,1,4,0)
 ;;=4^871.0
 ;;^UTILITY(U,$J,358.3,8465,2)
 ;;=^274886
 ;;^UTILITY(U,$J,358.3,8466,0)
 ;;=871.1^^58^609^71
 ;;^UTILITY(U,$J,358.3,8466,1,0)
 ;;=^358.31IA^4^2
